SecBot SecBot
ANALYST-UPGRADE ·Filed Aug 25, 2026

MRNA

Moderna, Inc.
MIXED
Impact 1/10
Horizonmonths Processed2mo ago SECanalyst-MRNA-wolferes-20260825
Wolfe Research double upgrade: Underperform → Peer Perform
Actionable Insight ◆ Mixed

This upgrade lacks conviction without a price target and is partially offset by heavy insider selling. Traders should treat this as a neutral signal and wait for a price target or additional catalysts before acting.

DirectionMixed
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$158.83
T+0 close · Aug 25, 2026 · via day close
Latest settled
+14.66%
T+20 · $182.11 · next T+60 tomorrow
Vs SPY
+13.68%
α at T+20
Latest observation
+64.71%
T+58 · FF3 residual α
  1. T+0 · Aug 25 $158.83entry
  2. T+1 · 3mo ago −5.77%α −5.80% · $149.66
  3. T+5 · 3mo ago −2.87%α −2.33% · $154.27
  4. T+20 · 8w ago +14.66%α +13.68% · $182.11
  5. T+58 · todayOpen
  6. T+60 · tomorrow Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Wolfe Research double-upgraded MRNA from Underperform to Peer Perform on August 25, 2026, a notable shift from a bearish stance to a neutral-equivalent rating. The firm's track record is average at 52% accuracy on 451 calls with a 4.4% average return. Consensus on MRNA is heavily tilted toward the sidelines: 30% Buy (9 of 30), 60% Hold (18), and 10% Sell (3). The mean price target of $95.67 implies 31% downside from the current $138.89, while the median of $83 suggests deeper downside. Momentum is mixed, 2 upgrades in 30 days (including this one) and 0 downgrades, but EPS revisions for the current fiscal year show 13 upward revisions vs 5 downward, a net positive. Insider selling is significant: CEO Stephane Bancel sold $28.7M worth on August 5, and the CFO sold $3.6M in July, creating a bearish divergence with the upgrade. Short interest is elevated at 62.3% of float, indicating heavy bearish positioning. The bottom line: this is a low-conviction upgrade from an average-accuracy firm, partially offset by improving EPS revisions, but heavy insider selling and a bearish consensus cap the upside.

Impact Score

Base Score
1/7
LLM Adjustment
+0
Final Score
1/10

Consensus & Targets

Buy / Strong Buy
9 (30%)
Hold
18
Sell / Strong Sell
3
Total Analysts
18
Mean PT
$95.67
Median PT
$83.00
High PT
$170.00
Low PT
$25.00
Current Price
$138.89
Implied Upside
-31.1%

Consensus is 30% Buy (2 Strong Buy, 7 Buy), 60% Hold (18 Hold), and 10% Sell (2 Sell, 1 Strong Sell) from 30 analysts. The consensus is heavily tilted toward the sidelines, with a majority neutral stance and a minority bearish.

Current price is $138.89. Mean target is $95.67 (31% downside), median $83 (40% downside), high $170 (22% upside), low $25 (82% downside). Wolfe Research did not provide a price target, so its view sits outside the consensus range, but the Peer Perform grade aligns with the consensus's neutral lean.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-08-25Wolfe ResearchupgradePeer PerformNo target
2026-08-24BarclaysmaintainEqual-Weight$125.00
2026-08-21JP MorganmaintainUnderweight$77.00
2026-08-20Goldman SachsmaintainNeutral$120.00
2026-08-20UBSmaintainNeutral$150.00
2026-08-20Morgan StanleymaintainEqual-Weight$89.00
2026-08-19William BlairupgradeOutperformNo target
2026-08-03CitigroupmaintainNeutral$60.00
2026-07-21Goldman SachsmaintainNeutralNo target
2026-07-08Morgan StanleymaintainEqual-Weight$39.00

In the last 30 days, there have been 2 upgrades (Wolfe Research and William Blair) and 0 downgrades. EPS revisions for the current fiscal year show 13 upward revisions vs 5 downward in the last 30 days, with the average EPS estimate improving from -$8.66 to -$8.58. For the next quarter, 11 upward revisions vs 3 downward, with EPS improving from -$2.06 to -$1.87. Estimates are being revised higher overall.

Firm Track Record: Wolfe Research

Wolfe Research accuracy: 52% on 451 calls | avg return: 4.4%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 13 firms with ≥5 scored calls.

FirmAccuracyCallsAvg Returnvs Average
Jefferies100%2/242.6%top tier
Morgan Stanley75%3/426.9%top tier
B of A Securities67%2/310%top tier
Leerink Partners50%1/248.9%below average
Citigroup50%1/231.7%below average
JP Morgan50%3/6-7.9%below average
RBC Capital38%3/8-7.9%below average
Needham38%3/8-14.3%below average
Barclays33%2/6-7.5%below average
Piper Sandler25%1/44.5%below average

Wolfe Research has a 52% accuracy rate on 451 calls with a 4.4% average return, ranking as average. Among firms covering MRNA, Jefferies (100% on 2 calls, 42.6% avg return) and Morgan Stanley (75% on 4 calls, 26.9% avg return) are top-tier. Oppenheimer (0% on 2 calls, -41.8% avg return) and Evercore ISI (0% on 4 calls, -29.1% avg return) are the worst performers.

Earnings Estimates

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
0q$-1.35$-3.32 to $-0.80$872.9M↑7 ↓0
+1q$-1.87$-2.31 to $-1.20$689.9M↑11 ↓0
0y$-8.58$-10.55 to $-8.00$2.1B↑7 ↓0
+1y$-4.87$-7.11 to $-2.73$2.5B↑8 ↓0

Cross-Platform Signals

Insider Trades (90d)
0 buys / 5 sells
Institutional
INTECH INVESTMENT MANAGEMENT LLC: near_exit (-76.6%)
Institutional
Brevan Howard Capital Management LP: doubled (102.1%)
Institutional
Jefferies Financial Group Inc.: add (30.2%)
Short Interest
Short: 10,829,917 | Exempt: 1,116,581 | TRF Vol: 17,371,198 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)

Insider trades show heavy selling: CEO Stephane Bancel sold $28.7M on August 5, and CFO Stephen Hoge sold $3.6M on July 15, a bearish signal that diverges from the upgrade. No congressional trades reported. Institutional activity is mixed: Brevan Howard doubled its position (+102.1%, $12.7M), while INTECH nearly exited (-76.6%, $319K). Short interest is elevated at 62.3% of float, indicating heavy bearish positioning that could fuel a squeeze if positive catalysts emerge. The upgrade is a contrarian signal against insider selling and high short interest.

Investment Themes

Documents Analyzed

Report based on filing metadata.

Track record

26 reports on MRNA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 25, 2026